Masimo Co. (NASDAQ:MASI) Holdings Lifted by Guggenheim Capital LLC

Guggenheim Capital LLC raised its holdings in Masimo Co. (NASDAQ:MASI - Free Report) by 61.5% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 7,021 shares of the medical equipment provider's stock after acquiring an additional 2,674 shares during the quarter. Guggenheim Capital LLC's holdings in Masimo were worth $1,161,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors and hedge funds also recently bought and sold shares of MASI. FMR LLC lifted its stake in Masimo by 19.8% during the fourth quarter. FMR LLC now owns 8,097,454 shares of the medical equipment provider's stock valued at $1,338,509,000 after purchasing an additional 1,340,836 shares during the last quarter. Vanguard Group Inc. lifted its position in shares of Masimo by 1.5% during the 4th quarter. Vanguard Group Inc. now owns 4,586,702 shares of the medical equipment provider's stock valued at $758,182,000 after acquiring an additional 66,215 shares during the last quarter. Massachusetts Financial Services Co. MA boosted its stake in shares of Masimo by 119.0% during the 4th quarter. Massachusetts Financial Services Co. MA now owns 1,735,167 shares of the medical equipment provider's stock worth $286,823,000 after acquiring an additional 943,001 shares in the last quarter. Alliancebernstein L.P. grew its holdings in shares of Masimo by 1,276.9% in the 4th quarter. Alliancebernstein L.P. now owns 947,391 shares of the medical equipment provider's stock worth $156,604,000 after acquiring an additional 878,587 shares during the last quarter. Finally, Geode Capital Management LLC raised its position in shares of Masimo by 1.0% during the fourth quarter. Geode Capital Management LLC now owns 801,125 shares of the medical equipment provider's stock worth $132,465,000 after purchasing an additional 8,239 shares during the period. 85.96% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling

In other Masimo news, Director Craig B. Reynolds sold 2,053 shares of the company's stock in a transaction dated Friday, March 14th. The stock was sold at an average price of $166.13, for a total value of $341,064.89. Following the transaction, the director now directly owns 16,581 shares of the company's stock, valued at $2,754,601.53. This represents a 11.02 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, COO Bilal Muhsin sold 30,000 shares of Masimo stock in a transaction dated Monday, March 10th. The shares were sold at an average price of $167.49, for a total value of $5,024,700.00. Following the sale, the chief operating officer now owns 24,172 shares of the company's stock, valued at approximately $4,048,568.28. This represents a 55.38 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 9.70% of the stock is owned by corporate insiders.

Analyst Upgrades and Downgrades

MASI has been the topic of a number of analyst reports. Raymond James lifted their price target on Masimo from $170.00 to $194.00 and gave the stock an "outperform" rating in a research note on Friday, December 27th. Needham & Company LLC reissued a "hold" rating on shares of Masimo in a research report on Thursday, April 10th. Wells Fargo & Company upped their price target on shares of Masimo from $193.00 to $205.00 and gave the company an "overweight" rating in a research report on Wednesday, February 26th. Finally, Piper Sandler raised their price objective on shares of Masimo from $210.00 to $215.00 and gave the stock an "overweight" rating in a research note on Wednesday, February 26th. One analyst has rated the stock with a hold rating and five have issued a buy rating to the stock. According to MarketBeat, Masimo presently has an average rating of "Moderate Buy" and a consensus price target of $194.80.

Masimo Price Performance

Shares of MASI opened at $152.07 on Wednesday. The company has a debt-to-equity ratio of 0.50, a current ratio of 2.01 and a quick ratio of 1.11. The company has a market capitalization of $8.22 billion, a price-to-earnings ratio of 104.88 and a beta of 1.28. The business's 50-day moving average is $166.89 and its 200-day moving average is $165.11. Masimo Co. has a fifty-two week low of $101.61 and a fifty-two week high of $194.88.

Masimo (NASDAQ:MASI - Get Free Report) last released its quarterly earnings data on Tuesday, February 25th. The medical equipment provider reported $1.80 earnings per share for the quarter, beating the consensus estimate of $1.42 by $0.38. The firm had revenue of $600.70 million for the quarter, compared to analyst estimates of $593.35 million. Masimo had a net margin of 3.85% and a return on equity of 14.98%. Equities research analysts expect that Masimo Co. will post 4.1 EPS for the current fiscal year.

Masimo Profile

Masimo Corporation develops, manufactures, and markets various patient monitoring technologies, and automation and connectivity solutions worldwide. The company offers masimo signal extraction technology (SET) pulse oximetry with measure-through motion and low perfusion pulse oximetry monitoring to address the primary limitations of conventional pulse oximetry; Masimo rainbow SET platform, including rainbow SET Pulse CO-Oximetry products that allows noninvasive monitoring of carboxyhemoglobin, methemoglobin, hemoglobin concentration, fractional arterial oxygen saturation, oxygen content, pleth variability index, rainbow pleth variability index, respiration rate from the pleth, and oxygen reserve index, as well as acoustic respiration monitoring, SedLine brain function monitoring, NomoLine capnography and gas monitoring, and regional oximetry.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.